ICHNO-ECHNO 2022 - Abstract Book

S41

ICHNO-ECHNO 2022

Materials and Methods Patients diagnosed with HPV+ SCCOP between January 2013 and August 2018 were identified through histopathology database interrogation and electronic medical notes were retrospectively reviewed. HPV positivity was determined via p16 immunostaining. AJCC TNM version 7 was applied prospectively. Statistical analysis was performed using SPSS v.26 (IBM Corp Armonk, NY, USA), and univariate and multivariate analysis completed using Cox Regression. Results One-hundred and twenty-two consecutive patients were included. Eighty-seven (72%) were male. Median age at diagnosis was 58 years (range 30-92). Primary sites were tonsillar=62 (51%), tongue base=52 (43%) and unknown primary=8 (7%). Smoking status was never=51 (42%), previous=43 (35%), current=16 (13%), or unknown=12 (10%). Stage at diagnosis was I=1 (1%), II=7 (6%), III=13 (11%), IVa=90 (74%), IVb=8 (7%), IVc=2 (2%). One-hundred and nineteen were treated radically with definitive surgery=15 (12%), surgery then radiotherapy +/- concurrent systemic therapy (cST)=53 (43%), or definitive radiotherapy +/- cST=51 (42%) with 5 receiving neoadjuvant chemotherapy. Median follow up was 54 months. Site of first relapse was loco-regional=7 (6%), distant=4 (3%), or both=4 (3%), and median time to first relapse was 11 months. Three-year survival was 88%. Cause of death was HPV+ SCCOP=15 (12%), second malignancy=2 (2%), treatment complications=2 (2%), or other=1 (1%). Receiving neoadjuvant treatment was the only significant predictor for death (Hazard Ratio [HR] 23.45, 95% Confidence Interval [CI] 1.56 - 358.26, p=0.02), with a trend towards unfavourable outcome for females (HR 2.65, 95% CI 0.84-9.25, p=0.10).

Conclusion In an unselected UK cohort, comparable survival rates were achieved. Neoadjuvant therapy, a surrogate for advanced disease, was the only significant predictor for death in our patient group. Identifying robust biomarkers for poor prognosis, together with treatment intensification strategies, should be central to future research.

PO-0074 Human papillomavirus (HPV) infection in Saudi patients with head and neck squamous cell carcinoma

G. Alsbeih 1 , N. Al-Harbi 1 , S. Bin Judia 1 , H. Khoja 2 , A. Tulbah 2

1 King Faisal Specialist Hospital and Research Centre, Biomedical Physics, Riyadh, Saudi Arabia; 2 King Faisal Specialist Hospital and Research Centre, Pathology & Laboratory Medicine, Riyadh, Saudi Arabia Purpose or Objective Human papillomavirus (HPV) emerges as an independent risk factor in about 30% of head and neck squamous cell carcinomas (HNSCC), mostly in the oropharynx. Those tumors are marked with a more favorable prognosis and targeted for stratification in the TNM-8. We have conducted a study to determine HPV-prevalence and its association with overall-survival (OS) in Saudi HNSCC patients. Materials and Methods HNSCC diagnosed between 2002 and 2016 were reviewed and 285 oropharyngeal and oral cavity patients were so far included in the study. HPV-Linear-Array and RealLine-HPV-HCR were used to detect and genotype HPV in tumor sections. Results There were 165 males and 120 females. Patients’ age ranged between 22 and 90 (median 57). HNSCC incidence peaked at 59 years old. Oropharyngeal cancers (28 cases) were infrequent (10%) compared to oral cavity (257 cases) with no difference in incidence by age or gender. The stage of the tumors varied with 63% of patients having early stage (T1–2) compared to 37% with advanced (T3–4) tumors. Patients underwent standardized curative treatment according to the stage of the tumor. The length of patients’ follow-up extended to 15 years (mean = 4.4 years; standard deviation = 3.9) after diagnosis. Univariate analysis showed significant association with patients’ OS for age (P<0.001), smoking (P=0.02), and tumor stage